IRB Study Number 20-295
Status Recruiting
Institute Taussig Cancer Institute
Description
Primary Objective
Evaluate safety and tolerability of NR supplementation peri-HCT from day -14 to day +7, +14, or +21
Safety is defined by percent of participants receiving NR experiencing a CTCAE 5.0 grade 3 or higher that is related to the study drug.
Tolerability is defined as percent of participants receiving NR who receive >75% of scheduled doses.
Secondary Objective(s)
Evaluate neutrophil and platelet recovery after HCT
Inclusion Criteria
4.1.1 All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
4.1.2 Age >18 years
4.1.3 Subject must meet program eligibility criteria* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
4.1.4 HLA-identical related donor or unrelated human donor source with bone marrow graft.
4.1.5 Subjects must provide a written informed consent.
Exclusion Criteria
4.2.1 History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
4.2.2 Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
4.2.3 Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
